Amundi Sarepta Therapeutics, Inc. Transaction History

Amundi

$264 Billion
Q3 2024

A detailed history of Amundi transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Amundi holds 357,919 shares of SRPT stock, worth $37.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

357,919

Previous 332,956 7.5%

Holding current value

$37.4 Million

Previous $52.6 Million 15.02%

% of portfolio

0.02%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$124.33 - $156.75 $3.1 Million - $3.91 Million	24,963 Added 7.5%	357,919 $44.7 Million
Q2 2024 Aug 14, 2024	SELL	$113.33 - $163.85 $7.4 Million - $10.7 Million	-65,330 Reduced 16.4%	332,956 $52.6 Million
Q1 2024 May 15, 2024	SELL	$93.7 - $141.53 $101,289 - $152,993	-1,081 Reduced 0.27%	398,286 $51.6 Million
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $6.18 Million - $11.5 Million	91,880 Added 29.88%	399,367 $38.5 Million
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $208,690 - $251,629	2,036 Added 0.67%	307,487 $37.3 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $9.82 Million - $14.5 Million	92,319 Added 43.32%	305,451 $35 Million
Q1 2023 May 15, 2023	BUY	$117.53 - $155.99 $22 Million - $29.2 Million	187,369 Added 727.28%	213,132 $29.4 Million
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $2.36 Million - $3.09 Million	23,359 Added 971.67%	25,763 $3.34 Million
Q3 2021 Nov 15, 2021	SELL	$65.97 - $92.48 $967,845 - $1.36 Million	-14,671 Reduced 85.92%	2,404 $222,000
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $1.18 Million - $1.48 Million	17,075 New	17,075 $1.33 Million

Others Institutions Holding SRPT

# of Institutions

532

Shares Held

84.5M

Call Options Held

2.06M

Put Options Held

1.52M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.15B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account